Remarkably, the engineered NKG2C-NKCE was as effective as a CD16-NKCE in controlling tumor formation in mice, even though NKG2C expression on NKG2C-positive adoptive NK cells was much lower than that of CD16 (86). This evidence concerns the gene FCGR3A and neoplasm.